Delays in the diagnosis of lung cancer Full Text
Journal of Thoracic Disease,  Clinical Article

Ellis PM et al. – Lung cancer patients experience substantial delays from development of symptoms to first initiating treatment. There is a need to promote awareness of lung cancer symptoms and develop and evaluate rapid assessment clinics for patients with suspected lung cancers.


  • Prospective cohort of patients referred with newly diagnosed lung cancer
  • Surveyed over 3 month period to assess delays in diagnosis
  • Patients reported when they first experienced symptoms, saw their doctor, what tests were done, when they saw a specialist and when they started treatment
  • Descriptive statistics used to summarize different time intervals

  • 56 of 73 patients consented (RR 77%)
  • 52 patients (30M, 22F) were interviewed (2 died before being interviewed and 2 could not be contacted)
  • The mean age was 68yrs
  • Stage distribution was as follows (IB/IIA 10%, stage IIIA 20%, IIIB/IV 70%)
  • Patients waited median of 21 days (iqr 7-51d) before seeing a doctor and further 22d (iqr 0-38d) to complete any investigations
  • Median time from presentation to specialist referral was 27d (iqr 12-49d) and further 23.5d (iqr 10-56d) to complete investigations
  • Median wait to start treatment once patients were seen at cancer centre was 10d (iqr 2-28d)
  • Overall time from development of first symptoms to starting treatment 138d (iqr 79-175d)

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Peanut component linked to cancer spread University of Liverpool News, December 23, 2014

2 Study: How red wine prevents cancer University of Colorado Health News, December 5, 2014

3 Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial The Lancet Oncology, October 24, 2014    Clinical Article

4 'Flying carpet' technique delivers one-two punch of anticancer drugs UNC Health Care System, January 15, 2015

5 New hope to prevent chemotherapy side effects The University of Adelaide News, January 13, 2015

6 Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial The Lancet Oncology, December 24, 2014    Clinical Article

7 Cancer treatment potential discovered in gene repair mechanism Case Western Reserve University School of Medicine News, January 6, 2015

8 Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial The Lancet Oncology, January 24, 2014    Clinical Article

9 Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): A randomised, controlled, open-label phase 2 trial The Lancet Oncology, January 27, 2015    Clinical Article

10 Popular new year's resolution may decrease cancer risk University of Colorado Health News, January 7, 2015

11 Impact of the U.S. preventive services task force recommendations against PSA screening on prostate biopsy and cancer detection rates The Journal of Urology, December 10, 2014    Clinical Article

12 Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: A meta-analysis Full Text JAMA, April 11, 2014    Free full text    Evidence Based Medicine    Clinical Article

13 Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: The Cancer-DACUS Study Journal of Clinical Oncology, October 10, 2014    Clinical Article

14 Toughest breast cancer may have met its match Johns Hopkins Medicine, December 11, 2014

15 Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes and comparison to de novo hodgkin lymphoma American Journal of Hematology, January 19, 2015    Clinical Article

16 The dirty side of soap UC San Diego Health System, November 20, 2014

17 Coffee intake and gastric cancer risk Cancer Epidemiology, Biomarkers & Prevention, March 20, 2014    Clinical Article

18 Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial The Lancet, January 7, 2015    Evidence Based Medicine    Clinical Article

19 Neutrophil to lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: Data from two randomized phase III trials Annals of Oncology, December 18, 2014    Clinical Article

20 Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: The FACS randomized clinical trial Full Text JAMA, January 16, 2014    Free full text    Evidence Based Medicine    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List